IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10941115 B1

PDFFull Text
Date of Patent:
Mar. 09, 2021

Filed:

Jul. 10, 2019

Kinase inhibitors

Applicant:

Oxular Acquisitions Limited, Oxford, GB;

Inventors:

Thomas Matthew Baker, Nottingham, GB;

Matthew Colin Thor Fyfe, London, GB;

Geraint Jones, Nottingham, GB;

Stephen Malcolm Thom, Nottingham, GB;

Assignee:

Oxular Acquisitions Limited, Oxford, GB;

Attorneys:

McCarter & English, LLP

Steven G. Davis

Wei Song

Primary Examiner:

Mark L Shibuya

Assistant Examiner:

Ebenezer O Sackey

Int. Cl.
CPC ...
C07D 213/74 (2006.01); C07F 9/6512 (2006.01); C07H 19/048 (2006.01); C07F 9/59 (2006.01); C07F 9/6503 (2006.01); A61K 31/505 (2006.01); A61K 31/444 (2006.01); A61K 45/06 (2006.01); A61K 31/635 (2006.01); A61K 31/4375 (2006.01); A61K 31/7052 (2006.01); A61K 31/4412 (2006.01); C07D 405/12 (2006.01); A61K 31/541 (2006.01); A61K 31/551 (2006.01); A61K 31/553 (2006.01); C07F 9/58 (2006.01); A61K 31/44 (2006.01); A61K 31/506 (2006.01); A61K 31/675 (2006.01); C07D 213/80 (2006.01); C07D 401/12 (2006.01); C07D 239/47 (2006.01); C07D 413/12 (2006.01); C07D 453/02 (2006.01); C07F 9/6558 (2006.01); C07H 13/08 (2006.01); C07H 15/26 (2006.01); A61K 31/4439 (2006.01); A61K 31/4545 (2006.01); A61K 31/496 (2006.01); A61K 31/5377 (2006.01); A61K 31/706 (2006.01);
U.S. Cl.
CPC ...
C07D 213/74 (2013.01); A61K 31/4375 (2013.01); A61K 31/44 (2013.01); A61K 31/444 (2013.01); A61K 31/4412 (2013.01); A61K 31/4439 (2013.01); A61K 31/4545 (2013.01); A61K 31/496 (2013.01); A61K 31/505 (2013.01); A61K 31/506 (2013.01); A61K 31/5377 (2013.01); A61K 31/541 (2013.01); A61K 31/551 (2013.01); A61K 31/553 (2013.01); A61K 31/635 (2013.01); A61K 31/675 (2013.01); A61K 31/706 (2013.01); A61K 31/7052 (2013.01); A61K 45/06 (2013.01); C07D 213/80 (2013.01); C07D 239/47 (2013.01); C07D 401/12 (2013.01); C07D 405/12 (2013.01); C07D 413/12 (2013.01); C07D 453/02 (2013.01); C07F 9/58 (2013.01); C07F 9/59 (2013.01); C07F 9/6512 (2013.01); C07F 9/65031 (2013.01); C07F 9/65583 (2013.01); C07H 13/08 (2013.01); C07H 15/26 (2013.01); C07H 19/048 (2013.01);
Abstract

There are provided compounds of formula I, wherein Rto R, Rto R, R, L and Xto Xhave meanings given in the description, which compounds have anti-inflammatory activity (e.g. through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.

Find Patent Forward Citations

Loading…